18.35  0.95 (5.46%)		10-22 16:00
Open: 17.45 High: 18.79 Volume: 1,763,386		Pre. Close: 17.4 Low: 17.22 Market Cap: 1,156(M)

Short term
Mid term
Targets	6-month :	23.43	1-year :	27.36
Resists	First :	20.05	Second :	23.43
Pivot price	17.36
Supports	First :	17.87	Second :	16.52
MAs	MA(5) :	17.49	MA(20) :	17.66
	MA(100) :	19.46	MA(250) :	18.82
MACD	MACD :	-0.5	Signal :	-0.6
%K %D	K(14,3) :	52.7	D(3) :	39.4
RSI	RSI(14): 54.4
52-week	High :	22	Low :	16.52

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ INVA ] has closed Bollinger Bands are 45.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	18.81 - 18.89	18.89 - 18.96
Low:	17.04 - 17.12	17.12 - 17.2
Close:	18.22 - 18.35	18.35 - 18.47

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Thu, 23 Oct 2025
Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength? - Nasdaq

Wed, 22 Oct 2025
Will Promising Zoliflodacin Data at IDWeek 2025 Transform Innoviva's (INVA) Infectious Disease Narrative? - Yahoo Finance

Tue, 21 Oct 2025
Innoviva, Inc. (INVA) Stock Analysis: Uncovering a 110% Upside Potential in the Biotechnology Space - DirectorsTalk Interviews

Mon, 20 Oct 2025
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 - Business Wire

Thu, 16 Oct 2025
Earnings Beat and Shifting Stakes Might Change the Case for Investing in Innoviva (INVA) - simplywall.st

Tue, 14 Oct 2025
Innoviva, Inc. (INVA) Stock Analysis: Exploring a Potential 113.70% Upside for Savvy Investors - DirectorsTalk Interviews

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	63 (M)
Shares Float	58 (M)
Held by Insiders	0.9 (%)
Held by Institutions	119.9 (%)
Shares Short	6,810 (K)
Shares Short P.Month	6,730 (K)

EPS	0.56
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	11.34
Profit Margin	10.4 %
Operating Margin	48.6 %
Return on Assets (ttm)	8.8 %
Return on Equity (ttm)	5.5 %
Qtrly Rev. Growth	0.4 %
Gross Profit (p.s.)	5.04
Sales Per Share	5.87
EBITDA (p.s.)	3.28
Qtrly Earnings Growth	0 %
Operating Cash Flow	201 (M)
Levered Free Cash Flow	154 (M)

PE Ratio	32.19
PEG Ratio	0
Price to Book value	1.61
Price to Sales	3.12
Price to Cash Flow	5.76

Dividend	0.25
Forward Dividend	0
Dividend Yield	1.3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.